From humble beginnings in 1983, Sun Pharma has grown into a leading specialty generic company worldwide and the No. 1 pharmaceutical company in India. In the U.S., we are amongst the leading specialty generic companies and are ranked No. 2 in generic dermatology by prescriptions. We have a presence in 80 countries across emerging markets, with Brazil, Mexico, Russia, Romania, and South Africa being some of the key markets. We maintain a strong footprint across Western Europe, Canada, Australia, New Zealand, Israel and Japan.
Recent Posts
- SPIL Q4FY26 Financial Results
- Press Release Sun Pharma reports Q4 & full year results for FY26
- Sun Pharma signs Definitive Agreement to Acquire Organon
- Sun Pharma launches its semaglutide injection under the brand names, Noveltreat and Sematrinity in India
- Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA® (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis
Recent Comments